Veraxa Biotech is trading 5% down at $1.14 on October 8, 2026, with biotech-sector weakness the most relevant context; no direct catalyst is confirmed. - The biotech sector is down 2.04%, while geopolitical and inflation concerns are pressuring markets. - The October 7 update on FDA-aligned preclinical testing preceded the prior session’s gain and does not clearly explain today’s decline.